MG
ITCI

Michael Gelband’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Michael Gelband’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,843
Closed -$2.49M – 2090
2025
Q1 		$2.49M Buy
18,843
+4,604
+32% +$574K 0.02% 623
2024
Q4 		$1.19M Buy
+14,239
New +$1.17M 0.01% 893
2024
Q1 		– Sell
-11,895
Closed -$852K – 2053
2023
Q4 		$852K Sell
11,895
-16,765
-58% -$964K 0.01% 868
2023
Q3 		$1.49M Sell
28,660
-11,298
-28% -$658K 0.01% 797
2023
Q2 		$2.53M Buy
+39,958
New +$2.49M 0.02% 712
2021
Q4 		– Sell
-6,859
Closed -$256K – 2689
2021
Q3 		$256K Buy
+6,859
New +$238K ﹤0.01% 1682
2020
Q4 		– Sell
-84,027
Closed -$2.16M – 2467
2020
Q3 		$2.16M Buy
+84,027
New +$1.92M 0.04% 376
2020
Q1 		– Sell
-16,490
Closed -$566K – 1738
2019
Q4 		$566K Buy
16,490
+4,108
+33% +$49.3K 0.01% 795
2019
Q3 		$92K Buy
12,382
+1,857
+18% +$17.8K ﹤0.01% 1243
2019
Q2 		$137K Buy
+10,525
New +$135K 0.01% 988

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Michael Gelband's ITCI Position: Q2 2025 in Review

Michael Gelband sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 18,843 shares — an estimated $2.49M sold.

Michael Gelband first reported a position in ITCI in Q2 2019 and held it in 10 quarters. The position peaked at $2.53M in Q2 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Michael Gelband reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Michael Gelband sold 18,843 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.49M.
  • Michael Gelband first reported a position in Intra-Cellular Therapies Inc. in Q2 2019 and held it in 10 quarters.
  • Michael Gelband's Intra-Cellular Therapies Inc. position peaked at $2.53M in Q2 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.